Elritercept for anemia in lower-risk myelodysplastic syndromes
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests elritercept, a medicine meant to improve anemia (low blood count) in adults with certain lower-risk bone marrow disorders called MDS. If you qualify, the study may help reduce the need for blood transfusions or improve anemia symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older and can give signed informed consent
- You have MDS that is classified as very low, low, or intermediate risk (or CMML for one part)
- Your bone marrow blast count is less than 5%
- Your anemia is significant based on hemoglobin level and/or recent red blood cell transfusions
- Your white blood cell count is below 13,000 (for key parts of the study)
- You can follow the study schedule and visit plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called elritercept for adults with a specific type of low-risk MDS (myelodysplastic syndromes) who have anemia (low red blood cells) and need regular blood transfusions. The goal is to see if elritercept can reduce or eliminate the need for transfusions.
This Phase 1/2 study tests luspatercept combined with another approach in people with low-risk myelodysplastic syndrome (MDS) who are not responding to or cannot use ESA (a common anemia treatment). It may help improve anemia (low hemoglobin), reduce transfusions, and control the disease if you fit the specific criteria.
This trial tests an investigational drug called DISC-0974 for people with myelofibrosis or certain types of MDS who have low red blood cell counts (anemia). The goal is to see if this treatment can help improve anemia and reduce the need for blood transfusions.
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
This trial tests an experimental drug, HS-20106, to see if it can improve low red blood cell counts (anemia) for people with a certain type of bone marrow disorder called myelodysplastic syndromes (MDS), which is not high risk. It might be an option if you have not received certain prior treatments.
This trial tests an investigational drug called TAK-226 for Japanese patients with a type of bone marrow disorder called lower-risk myelodysplastic syndromes (MDS) who have anemia. It aims to see if the drug can help reduce the need for red blood cell transfusions or improve symptoms like fatigue.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.